

Table 3.4
Verified Outcomes (Annualized Percentages) by Age at Enrollment for SRC Super Cohort Participants¹
 Data as of: February 19, 2022; Events through September 30, 2010 and February 19, 2022

	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
Outcomes through Extension Study 2005-2010					
Number randomized	117634	14781	22638	53171	27044
Mean follow-up (months)	142.7	154.9	151.9	142.9	128.1
Cardiovascular²					
CHD ³	5434 (0.39%)	201 (0.11%)	489 (0.17%)	2362 (0.37%)	2382 (0.83%)
CHD death ⁴	1891 (0.14%)	49 (0.03%)	104 (0.04%)	693 (0.11%)	1045 (0.36%)
Clinical MI	4044 (0.29%)	159 (0.08%)	398 (0.14%)	1834 (0.29%)	1653 (0.57%)
Angina ⁵	3623 (0.38%)	139 (0.11%)	423 (0.22%)	1749 (0.41%)	1312 (0.63%)
CABG/PTCA	6113 (0.44%)	241 (0.13%)	711 (0.25%)	3161 (0.50%)	2000 (0.69%)
Carotid artery disease	1111 (0.08%)	48 (0.03%)	117 (0.04%)	520 (0.08%)	426 (0.15%)
Congestive heart failure, WHI ⁵	2797 (0.29%)	78 (0.06%)	201 (0.11%)	1096 (0.26%)	1422 (0.68%)
Stroke	4259 (0.30%)	124 (0.06%)	322 (0.11%)	1857 (0.29%)	1956 (0.68%)
PAD	984 (0.07%)	24 (0.01%)	88 (0.03%)	460 (0.07%)	412 (0.14%)
Coronary disease ⁶	11771 (0.84%)	455 (0.24%)	1244 (0.43%)	5456 (0.86%)	4616 (1.60%)
Total cardiovascular disease	16777 (1.20%)	626 (0.33%)	1665 (0.58%)	7668 (1.21%)	6818 (2.36%)
Fractures²					
Hip fracture	2955 (0.21%)	63 (0.03%)	186 (0.06%)	1108 (0.18%)	1598 (0.55%)
Outcomes through Extension Study 2010-2025					
Number randomized	117634	14781	22638	53171	27044
Mean follow-up (months)	208.5	244.9	237.9	210.0	161.2
Cancer					
Breast cancer	11087 (0.54%)	1541 (0.51%)	2420 (0.54%)	5109 (0.55%)	2017 (0.56%)
Invasive breast cancer	9345 (0.46%)	1243 (0.41%)	2038 (0.45%)	4328 (0.47%)	1736 (0.48%)
In situ breast cancer	1935 (0.09%)	329 (0.11%)	425 (0.09%)	875 (0.09%)	306 (0.08%)
Ovarian cancer	1080 (0.05%)	131 (0.04%)	214 (0.05%)	515 (0.06%)	220 (0.06%)
Endometrial cancer ⁷	1575 (0.13%)	188 (0.10%)	362 (0.13%)	725 (0.13%)	300 (0.15%)
Colorectal cancer	2600 (0.13%)	161 (0.05%)	367 (0.08%)	1292 (0.14%)	780 (0.21%)
Other cancer ⁸	14764 (0.72%)	1519 (0.50%)	2632 (0.59%)	7231 (0.78%)	3382 (0.93%)
Total cancer	28200 (1.38%)	3219 (1.07%)	5436 (1.21%)	13384 (1.44%)	6161 (1.70%)
Deaths					
Cardiovascular deaths	11805 (0.58%)	259 (0.09%)	784 (0.17%)	5179 (0.56%)	5583 (1.54%)
Cancer deaths	10431 (0.51%)	689 (0.23%)	1531 (0.34%)	5200 (0.56%)	3011 (0.83%)
Other known cause	14703 (0.72%)	512 (0.17%)	1360 (0.30%)	7223 (0.78%)	5608 (1.54%)
Unknown cause	1872 (0.09%)	101 (0.03%)	262 (0.06%)	1029 (0.11%)	480 (0.13%)
Total death⁹	57028 (2.35%)	2143 (0.60%)	5288 (1.01%)	26488 (2.40%)	23109 (5.19%)

¹ The SRC Super Cohort includes all Non-Hispanic White, American Indian/Alaska Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants (identified from race/ethnicity collected on Form 2 at baseline) from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

² Cardiovascular diseases and hip fracture are not adjudicated for SRC Super Cohort participants during the WHI Extension Study 2010-2025. Reported statistics represent experience during the original program and the Extension Study 2005-2010.

³ "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Study 2005-2010.

⁴ "CHD death" includes definite and possible CHD death.

⁵ Angina and CHF are not verified outcomes in the WHI Extension Study 2005-2010. Reported statistics represent experience during the original program.

⁶ "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure were not collected in the WHI Extension Study 2005-2010.

⁷ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

⁸ Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

⁹ Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.